Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2877715 | The Annals of Thoracic Surgery | 2011 | 9 Pages |
Abstract
Cellular therapy has emerged as a potentially novel treatment for severe ischemic heart disease, and there is increasing evidence that stem cell transplantation may improve the perfusion and contractile function of ischemic myocardium. However, the problem of poor donor cell engraftment and survival in ischemic myocardium limits the successful use of cellular therapy for treating ischemic heart disease. This review discusses the state-of-the-art understanding of the low level of cell engraftment and cell survival after transplantation into the ischemic heart, with a focus on the approaches that have been investigated for supporting and improving the survival and engraftment of transplanted cells in this setting.
Keywords
PBSOPCABGADSCsFGF-2HIF-1αGMPangiopoietin-1SDF-1IGFMSCsAng-1Myocardial infarctioncoronary artery bypass graftingGood Manufacturing PracticeCABGoff-pump coronary artery bypass graftingICDCardioverter-defibrillatorES cellsMesenchymal stem cellsAdipose derived stem cellsBone marrow cellsEmbryonic stem cellsfibroblast growth factor 2stromal cell-derived factor 1Vascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Insulin-like growth factorPhosphate-buffered saline
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Kai Hong MD, Xu Ming MD, Zhong Chao MD, PhD, Bin PhD,